Why Haven’t I Lost Weight on Wegovy? Understanding the Challenges and Solutions

Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Thousands of patients start Wegovy expecting dramatic results, yet some experience minimal weight loss or hit a frustrating plateau after initial progress. Research shows that roughly 30% of GLP-1 users don't achieve their target weight loss goals, often due to dose restrictions, individual metabolic variation, or unaddressed genetic factors. Understanding why your current therapy isn't working—and what to do about it—can transform your weight loss journey.

Common Reasons Why Wegovy May Not Be Working for You

Wegovy's dosing is standardized for most patients, starting at 0.25 mg and escalating every four weeks up to 2.4 mg. This one-size-fits-most approach works well for many, but not everyone. Some patients experience intolerable side effects before reaching an effective dose, forcing them to stay at a subtherapeutic level. Others metabolize the medication differently due to genetic variation in GLP-1 receptor sensitivity, meaning a standard dose simply doesn't activate their appetite-suppression pathways strongly enough.

Insurance coverage limitations also play a significant role. Many patients must wait months between dose increases or switch medications entirely due to formulary restrictions. Additionally, weight loss plateaus occur when your body adapts to the medication—a process called tachyphylaxis—which happens faster in some individuals than others. Without dose flexibility or alternative compounds to rotate, progress stalls.

How Genetic Variation Affects Your GLP-1 Response

Your DNA influences how effectively semaglutide and tirzepatide work at the cellular level. Key genetic variants—including those in the GLP1R gene (rs6923761), GIPR gene (rs1800437), and appetite-regulating genes like FTO (rs9939609) and MC4R (rs17782313)—determine your baseline sensitivity to GLP-1 therapy. If you carry genetic variations that reduce GLP-1 receptor expression or signaling, a standard Wegovy dose may produce only modest results regardless of your commitment to the program.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Exploring Alternatives When Wegovy Reaches Its Limits

If Wegovy has stopped working or caused side effects, several evidence-based alternatives exist. Tirzepatide—a dual GLP-1 and GIP receptor agonist—activates two appetite-control pathways simultaneously, making it more potent than semaglutide alone. Clinical trials show tirzepatide produces 20–25% weight loss in some patients compared to 15–17% with semaglutide at comparable doses. For patients who need both compounds but want to avoid injectable fatigue, PlexusDx offers GLP-Squared Injection, a custom dual-compound formula that starts at $289/mo (or $249/mo on the 3-month plan), providing the synergistic benefits of both semaglutide and tirzepatide in a single weekly injection.

Oral formulations may also be worth considering if you prefer to avoid injections. PlexusDx offers Oral Semaglutide starting at $289/mo (or $249/mo on the 6-month plan) and Oral Tirzepatide starting at $349/mo (or $279/mo on the 6-month plan), both compounded to your specific dose and delivered directly. A microdose GLP-1 protocol is also available at $129/mo flat—ideal for patients seeking gentler appetite suppression or those restarting after a break. All PlexusDx medications are compounded by licensed 503A pharmacies and require no insurance, no membership fees, and are HSA/FSA eligible.

How Personalized GLP-1 Therapy Differs from Wegovy

The primary limitation of Wegovy is its fixed dosing schedule designed for the general population. PlexusDx takes a personalized approach: after your initial consultation, your dose can increase, decrease, or be adjusted based on your individual response and tolerance. The marketing principle is simple: 'Your dose may need to go up. Your price won't.' Whether you start at a microdose, increase to a full therapeutic dose, or rotate between compounds, your monthly cost remains flat—eliminating the financial barrier that keeps many Wegovy patients stuck at ineffective doses.

When combined with the Precision Peptide Genetic Test ($99 add-on after your first month), personalized therapy becomes predictive. Rather than guessing which compound will work best for your genetics, PlexusDx uses your genetic data to prioritize semaglutide, tirzepatide, or a dual approach. This genetic-first strategy reduces time to therapeutic response, improves tolerability, and increases the likelihood of reaching your weight loss goal. PlexusDx serves all 50 states with medications from licensed 503A compounding pharmacies—meaning your personalized therapy arrives at your door on your schedule, not your insurance company's.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Why am I not losing weight after three months on Wegovy?

Weight loss plateau on Wegovy often stems from dose limitations, genetic factors affecting GLP-1 receptor sensitivity, or side effects that prevent dose escalation. PlexusDx Precision Peptide Genetic Testing reveals whether your biology responds optimally to semaglutide or whether tirzepatide, a dual-compound protocol, or dose adjustment would work better for your genetic profile.

Is tirzepatide more effective than semaglutide for weight loss?

Clinical trials show tirzepatide produces greater weight loss than semaglutide when compared at equivalent doses—approximately 20–25% body weight reduction versus 15–17%. Tirzepatide activates both GLP-1 and GIP receptors, engaging two appetite-control pathways. For patients who don't respond adequately to semaglutide alone, PlexusDx offers Compounded Tirzepatide Injection starting at $289/mo (or $249/mo on the 6-month plan) or GLP-Squared dual-compound formulas.

How much does PlexusDx personalized GLP-1 therapy cost compared to Wegovy?

PlexusDx Compounded Semaglutide Injection starts at $189/mo (or $149/mo on the 6-month plan) flat—typically less expensive than Wegovy's out-of-pocket cost. Tirzepatide starts at $289/mo, and the Precision Peptide Genetic Test is a $99 one-time add-on after your first month. All prices remain flat regardless of dose, and treatment requires no insurance, no membership fee, and is HSA/FSA eligible.

Is compounded semaglutide from PlexusDx as safe as Wegovy?

PlexusDx compounds all medications at licensed 503A pharmacies under strict pharmaceutical standards. While compounded medications are not FDA-approved as branded products, 503A compounding pharmacies must meet rigorous quality, sterility, and potency requirements. Your PlexusDx clinician monitors you for side effects and adjusts your protocol accordingly, ensuring safety equivalent to branded GLP-1 therapy.

What does the PlexusDx Precision Peptide Genetic Test reveal?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.